Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04WQT
|
||||
| Former ID |
DNCL002913
|
||||
| Drug Name |
RG7201
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 3 | [532723] | ||
| Company |
Roche
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium/glucose cotransporter 2 | Target Info | Modulator | [532723] | |
| WikiPathways | NRF2 pathway | ||||
| References | |||||
| Ref 532723 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. | ||||
| Ref 532723 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.